Niagen Bioscience CEO Robert Fried discusses the science of NAD, the problems with the supplement industry, and how his company is leading the way in anti-aging research.

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Executives from Niagen Bioscience, Pushly, and VidaCorp discuss brand evolution. Learn why authenticity, community, and AI are key to building a resilient brand.

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

View the latest Niagen Bioscience Inc. (NAGE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-405-5227 [email protected]. Niagen Bioscience Investor Relations Contact: ...

Niagen Bioscience (NASDAQ:NAGE) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.

Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript May 10, 2025 Operator: Ladies and gentlemen, thank you for standing by, and welcome to Niagen Biosciences Inc. First Quarter of ...

LOS ANGELES, June 11, 2025--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of ...